These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 39179275)
21. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater. She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368 [TBL] [Abstract][Full Text] [Related]
22. Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy. Feng S; Wang Y; Cai K; Wu H; Xiong G; Wang H; Zhang Z PLoS One; 2015; 10(10):e0140794. PubMed ID: 26474174 [TBL] [Abstract][Full Text] [Related]
23. First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Shi YK; Wang L; Han BH; Li W; Yu P; Liu YP; Ding CM; Song X; Ma ZY; Ren XL; Feng JF; Zhang HL; Chen GY; Han XH; Wu N; Yao C; Song Y; Zhang SC; Song W; Liu XQ; Zhao SJ; Lin YC; Ye XQ; Li K; Shu YQ; Ding LM; Tan FL; Sun Y Ann Oncol; 2017 Oct; 28(10):2443-2450. PubMed ID: 28945850 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer. Aguiar PN; Haaland B; Park W; San Tan P; Del Giglio A; de Lima Lopes G JAMA Oncol; 2018 Aug; 4(8):1080-1084. PubMed ID: 29852038 [TBL] [Abstract][Full Text] [Related]
25. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations. Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China. Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645 [TBL] [Abstract][Full Text] [Related]
27. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231 [TBL] [Abstract][Full Text] [Related]
28. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations. Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784 [TBL] [Abstract][Full Text] [Related]
29. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China. Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554 [No Abstract] [Full Text] [Related]
30. Cost-utility of afatinib and gefitinib as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer. Wang H; Zeng C; Li X; Wang Y; Li X; Ge W Future Oncol; 2019 Jan; 15(2):181-191. PubMed ID: 30320506 [TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of atezolizumab as adjuvant treatment of patients with stage II-IIIA non-small cell lung cancer, PD-L1+≥50% of tumor cells in France: A modeling study. Plessala I; Cawston H; Cortes J; Ajjouri R; Le Lay K; Souquet PJ; Chouaid C Lung Cancer; 2023 Oct; 184():107316. PubMed ID: 37562344 [TBL] [Abstract][Full Text] [Related]
32. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. Liang W; Wu X; Fang W; Zhao Y; Yang Y; Hu Z; Xue C; Zhang J; Zhang J; Ma Y; Zhou T; Yan Y; Hou X; Qin T; Dinglin X; Tian Y; Huang P; Huang Y; Zhao H; Zhang L PLoS One; 2014; 9(2):e85245. PubMed ID: 24533047 [TBL] [Abstract][Full Text] [Related]
33. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study. Jiang Z; Zhang J; Sun H; Wang C; Zhang Y; Li Y; Pan Z Thorac Cancer; 2021 Sep; 12(17):2369-2374. PubMed ID: 34255422 [TBL] [Abstract][Full Text] [Related]
34. OPTIMAL and ENSURE trials-based combined cost-effectiveness analysis of erlotinib versus chemotherapy for the first-line treatment of Asian patients with non-squamous non-small-cell lung cancer. Wen F; Zheng H; Zhang P; Hutton D; Li Q BMJ Open; 2018 Apr; 8(4):e020128. PubMed ID: 29654023 [TBL] [Abstract][Full Text] [Related]
35. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666 [TBL] [Abstract][Full Text] [Related]
36. Pemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case report. Xu T; Wu H; Jin S; Min H; Zhang Z; Shu Y; Wen W; Guo R Medicine (Baltimore); 2017 Aug; 96(33):e7732. PubMed ID: 28816950 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France. Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550 [TBL] [Abstract][Full Text] [Related]
38. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes. Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808 [TBL] [Abstract][Full Text] [Related]
39. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Wong KM; Ding K; Li S; Bradbury P; Tsao MS; Der SD; Shepherd FA; Chung C; Ng R; Seymour L; Leighl NB Clin Lung Cancer; 2017 Jan; 18(1):e41-e47. PubMed ID: 27502323 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]